white → brown1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
WARNINGREDOSING CAN TRIGGER PSYCHOSIS
PCP-like dissociatives can cause mania, paranoia, or psychosis that outlasts the high. High doses, redosing, and sleep loss raise the risk.
4-MeO-PCP
4-Methoxyphencyclidine
Methoxydine, 4-Methoxy-PCP
4-MeO-PCP is an arylcyclohexylamine synthetic dissociative that can produce hallucinogenic and anesthetic effects. First synthesized in 1965 by Parke-Davis chemist Victor Maddox, it became the first arylcyclohexylamine research chemical sold online when it appeared in late 2008. It is reported to have reduced potency relative to PCP. Dosage information remains tentative, potentially due to variations in the potency of available supplies.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~25 mg
Light25-75 mg
Moderate75-150 mg
Strong150-250 mg
Heavy250+ mg
Dosage information for 4-MeO-PCP remains poorly characterized, and some user reports may involve misidentified substances. Sensitivity varies considerably between individuals, and dose-response relationships appear inconsistent.
Duration
Onset45-120 minutes
Come Up1-2 hours
Peak3-7 hours
Offset6-10 hours
After Effects6-12 hours
Total12-20 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
Cognitive
DepersonalizationDerealizationConsciousness disconnectionMemory suppressionEgo deathThought decelerationImmersion enhancementInformation processing suppressionTime distortionEuphoriaIntrospectionDéjà vuConceptual thinkingUnity and interconnectednessCompulsive redosingAnxiety suppressionDisinhibitionAmnesiaCreativity enhancement
Visual
Distortions
Auditory
See also: Dissociative Intensity Scale, Subjective Effects of Dissociatives
Pharmacology
Pharmacodynamics
4-MeO-PCP acts primarily as an NMDA receptor antagonist.1 Its NMDA affinity is lower than that of PCP but higher than that of ketamine. The compound also binds with notable affinity to σ1 and σ2 receptors, and shows moderate affinity for the norepinephrine and serotonin transporters.1 It is considered a relatively selective NMDA receptor ligand, lacking appreciable affinity for the dopamine transporter.1
Pharmacokinetics
4-MeO-PCP is orally active, indicating sufficient oral bioavailability for pharmacological effects. There have been no studies on the pharmacokinetic profile of 4-MeO-PCP and the metabolism of 4-MeO-PCP is unknown.
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
DepressantsStimulants
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
With sustained repeated use, many effects may weaken, requiring higher doses for comparable results.
Baseline Reset
1-2 weeks
Half Tolerance
3-7 days
Cross Tolerance
Dissociatives
Harm Potential
Addiction & Dependence
Psychological
ModerateChronic use can be moderately addictive with high potential for abuse and is capable of causing psychological dependence among certain users. Cravings may occur if usage is suddenly stopped.
Physical
LowWithdrawal effects have been reported upon cessation of chronic use, though specific physical withdrawal symptoms are not well characterized due to limited research history.
Toxicity
Urinary System
Repeated excessive use over extended periods may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency and urgency, pelvic and bladder pain, hematuria, and incontinence; these effects can be avoided by limiting use to less than weekly.
Psychosis Risk
Psychotic episodes, disturbing hallucinations, delusions, anxiety, and paranoia are reported as potential negative effects. Risk of adverse psychological reactions increases with higher doses and redosing.
History & Culture
4-MeO-PCP was originally synthesized in 1965 by Victor Maddox, a medicinal chemist working at the pharmaceutical company Parke-Davis. The compound remained largely obscure for decades following its initial creation.…
Legality
By Country
Illegal4
ChileIllegalProhibited under Ley 20000 (the Chilean drug control law), which explicitly covers all esters and ethers of phencyclidine.2 As 4-MeO-PCP is an ether of PCP, it falls under this provision.
GermanyIllegal (analog/blanket ban)Neue-psychoaktive-Stoffe-Gesetz (NpSG), consolidated official text3
The law's generic structural definition is the legal basis rather than a named 4-MeO-PCP entry; §3's listed conduct prohibition has statutory exceptions for recognized commercial, industrial or scientific uses.
SwedenIllegalFörordning (1992:1554) om kontroll av narkotika, 2 § and Bilaga 14
Sweden's public health agency recommended classifying 4-MeO-PCP as a hazardous substance on November 10, 2014.
TurkeyIllegalLaw No. 2313 on the Control of Narcotic Drugs (Uyuşturucu Maddelerin Murakabesi Hakkında Kanun), as amended by Council of Ministers Decision No. 2013/5742 dated 16 December 2013 and published in Official Gazette No. 28893 on 25 January 2014; Turkish Penal Code No. 5237 (TCK) Articles 188 and 191 for unauthorized manufacture, import/export, supply/trade, possession and use.111213141516
4-MeO-PCP is individually named in Annex 2 item 111 to Decision 2013/5742 and thereby brought under Law No. 2313. Turkey's NPS framework also uses generic classification (in operation since 2015), but this named entry has no separate generic or analogue designation. The latest official EGM report records continuing EWS and Law No. 2313 inclusion through 31 July 2025; official materials contain no repeal or exclusion of the specifically named entry. TCK Article 188 penalties are conduct-specific and include daily fines; Article 191 personal-use possession/use is 2-5 years subject to the statutory five-year deferred-prosecution, supervised-release and treatment mechanisms. The 188/4(a) half-increase for listed substance classes should not be assumed for 4-MeO-PCP merely from its NPS status.
Controlled / restricted3
SwitzerlandRestrictedBetäubungsmittelverzeichnisverordnung (BetmVV-EDI; SR 812.121.11), Articles 1–2 and Annex 6 Verzeichnis e item 103, consolidated text standing 13 March 20265678910
The exact substance is expressly named as item 103 in the binding BetmVV-EDI Annex 6 Verzeichnis e. Verzeichnis e is a distinct Article 7 BetmG category whose materials/products are subject to the control measures applicable to Verzeichnis-a narcotics and require the applicable EDI authorization framework. The item 103 line does not state a general industrial-use exception. Not every act involving 4-MeO-PCP is categorically prohibited, and Verzeichnis e is distinct from Verzeichnis d.
United KingdomClass BControlled under the Misuse of Drugs Act 1971. Covered by the arylcyclohexylamine generic clause added by S.I. 2013/239, which came into effect on February 26, 2013.17 This clause encompasses derivatives of 1-phenylcyclohexylamine where the amine has been replaced with a piperidyl group and further substituted in the phenyl ring with an alkoxy substituent.17 Possession, production, supply, and importation are prohibited.
References
Source Pages
Citations
- Bryan L. Roth, Simon Gibbons, Warunya Arunotayanun, Xi-Ping Huang, Vincent Setola, Ric Treble, & Les Iversen. (2013). The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLOS ONE, 8(3). https://doi.org/10.1371/journal.pone.0059334123
- Decreto 867: Reglamento de la Ley N° 20.000 que sanciona el tráfico ilícito de estupefacientes y sustancias sicotrópicas. Ministerio del Interior, Chile (2007). https://juridico1.minsal.cl/DECRETO_867_07_REGL_LEY%2020000_DROGAS.doc1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), consolidated official text. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/NpSG.pdf1
- Förordning (1992:1554) om kontroll av narkotika, 2 § and Bilaga 1. riksdagen.se (n.d.). https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/forordning-19921554-om-kontroll-av-narkotika_sfs-1992-1554/1
- Betäubungsmittelverzeichnisverordnung (BetmVV-EDI; SR 812.121.11), Articles 1–2 and Annex 6 Verzeichnis e item 103, consolidated text standing 13 March 2026. fedlex.admin.ch (n.d.). https://www.fedlex.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20260313/de/pdf-a/fedlex-data-admin-ch-eli-cc-2011-363-20260313-de-pdf-a-3.pdf1
- BetmVV-EDI (SR 812.121.11), official Fedlex authoritative consolidated XML metadata and text, applicable 13 March 2026. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20260313/de/xml/fedlex-data-admin-ch-eli-cc-2011-363-20260313-de-xml.xml1
- Betäubungsmittelkontrollverordnung (BetmKV; SR 812.121.1), Articles 3(2)(e), 5(2) and 11(1), consolidated text standing 23 January 2023. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/362/20230123/de/pdf-a/fedlex-data-admin-ch-eli-cc-2011-362-20230123-de-pdf-a.pdf1
- Betäubungsmittelgesetz (BetmG; SR 812.121), Article 7(1), consolidated text standing 1 September 2023. fedlex.admin.ch (n.d.). https://www.fedlex.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/1952/241_241_245/20230901/de/pdf-a/fedlex-data-admin-ch-eli-cc-1952-241_241_245-20230901-de-pdf-a.pdf1
- Listen und Verzeichnisse — Swissmedic, section 4 Betäubungsmittel und Vorläuferstoffe. swissmedic.ch (n.d.). https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html1
- Swissmedic, Verzeichnis der Rohmaterialien und Erzeugnisse mit vermuteter betäubungsmittelähnlicher Wirkung, standing 19 November 2024. swissmedic.ch (n.d.). https://www.swissmedic.ch/dam/swissmedic/de/dokumente/bewilligungen/btm/verzeichnis_der_rohmaterialienunderzeugnissemitvermuteterbetaeub.pdf.download.pdf/verzeichnis_der_rohmaterialienunderzeugnissemitvermuteterbetaeub.pdf1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 4-MeO-PCP article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
